The DOI matches its Crossref record; 163 of the 166 references it cites were found in a registry or an index.
A decade of exploring the cancer epigenome—biological and translational implications
Open accessAbstract
The past decade has highlighted the central role of epigenetic processes in cancer causation, progression and treatment. Next-generation sequencing is providing a window for visualizing the human epigenome and how it is altered in cancer. This view provides many surprises, including linking epigenetic abnormalities to mutations in genes that control DNA methylation, the packaging and the function of DNA in chromatin, and metabolism. Epigenetic alterations are leading candidates for the development of specific markers for cancer detection, diagnosis and prognosis. The enzymatic processes that control the epigenome present new opportunities for deriving therapeutic strategies designed to reverse transcriptional abnormalities that are inherent to the cancer epigenome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Conversely, disruption of chromosomal topology and oncogene insulation may be more generally relevant to methylator phenotypes observed in colorectal and renal cell carcinomas, leukemia and other malignancies28.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed that enhanced histone acetylation induced by HDACi allowed the overexpression of genes involved in cell cycle arrest such as cyclin-dependent kinase inhibitors or the growth arrest and DNA damage-inducible protein GADD45 gene family (11, 28, 40, 45-49).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Insulator dysfunction may also be accompanied by promoter silencing events28,29, and by alterations to other pathways affected by 2-HG7,30.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [28]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among them, novel selective benzamide-based HDAC1/2 inhibitors have been described that exhibit greater than 100-fold selectivity relative to other HDACs (11, 28).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It has previously been shown that HDAC inhibitors such as SAHA and MS-275 promote cell cycle arrest and apoptosis”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Among activated genes that subside with pulsed HDACi administration are genes known to be powerful effectors of cell cycle arrest in multiple cell types and may promote apoptosis (11, 50).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [11]
Experimental — accuracy not yet measuredIn the citing paper
“Three general processes have major effects on cancer initiation and progression. First, discrete somatic mutations lead to tumor suppressor loss-of-function and oncoprotein gain-of-function [1]; second, epigenetic alterations change patterns of gene expression [2]; and third, alterations in the tumor microenvironment also lead to broad changes in gene expression [3].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
DNA methylation patterns and epigenetic memory
Bird, A. (2002) · Genes & Development · doi:10.1101/gad.947102 · Cited by 7,124
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Self-citationA bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
Gupta, R. A., Shah, N., Wang, K., Kim, J., Horlings, H. M., Wong, D. J., Tsai, M.-C., Hung, T., Argani, P., Rinn, J. L., et al. (2010) · Nature · doi:10.1038/nature08975 · Cited by 5,205
Flagged first, then by citations
3 of the 166 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- Allis, C., Jenuwein, T. & Reinberg, D. Epigenetics (ed. Caparros, M.) (Cold Spring Harbor Laboratory Press, 2007).
- Allis, C. D., Jenuwein, T, Reinberg, D. Overview and concepts (Cold Spring Harbor Laboratory Press, New York, 2007).
- Gilbert, M. R. et al. in ASCO Annual Meeting 2011 Abstr. 2006. (University of Texas M. D. Anderson Cancer Center, Chicago, 2011).
Cited by
Sorted by citations
Items 401–500 of 1,001
The role of 5-hydroxymethylcytosine in development, aging and age-related diseases
López, V., Fernández, A. F., & Fraga, M. F. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.002 · Cited by 101
Matsushima-Miyagi, T., Hatano, K., Nomura, M., Liu, L., Nishikawa, T., Saga, K., Shimbo, T., & Kaneda, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1595 · Cited by 96
Li, Z., Dai, H., Martos, S. N., Xu, B., Gao, Y., Teng, L., Zhu, G., Schones, D. E., & Wang, Z. (2015) · Genome biology · doi:10.1186/s13059-015-0685-2 · Cited by 96
Epigenetic dysregulation of KCa3.1 channels induces poor prognosis in lung cancer
Bulk, E., Ay, A., Hammadi, M., Ouadid‐Ahidouch, H., Schelhaas, S., Hascher, A., Rohde, C., Thoennissen, N. H., Wiewrodt, R. G., Schmidt, E., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29490 · Cited by 96
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 95
Clark, C., Palta, P., Joyce, C. J., Scott, C., Grundberg, E., Deloukas, P., Palotie, A. V., & Coffey, A. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050233 · Cited by 94
Analysis of chromatin accessibility uncovers TEAD1 as a regulator of migration in human glioblastoma
Tomé-García, J., Erfani, P., Nudelman, G., Tsankov, A. M., Katsyv, I., Tejero, R., Zhang, B., Walsh, M. J., Friedel, R. H., Zaslavsky, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06258-2 · Cited by 91
The Histone Code of Senescence
Paluvai, H., Giorgio, E. D., & Brancolini, C. (2020) · Cells · doi:10.3390/cells9020466 · Cited by 97
Chung, J.-H., Karkhanis, V. A., Tae, S., Yan, F., Smith, P. L., Ayers, L. W., Agostinelli, C., Pileri, S. A., Denis, G. V., Baiocchi, R. A., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.510669 · Cited by 97
BET Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-Dimensional Collagen
Sahai, V., Kumar, K., Knab, L. M., Chow, C. R., Raza, S. S., Bentrem, D. J., Ebine, K., & Munshi, H. G. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0925 · Cited by 98
Aging is associated with highly defined epigenetic changes in the human epidermis
Raddatz, G., Hagemann, S., Aran, D., Söhle, J., Kulkarni, P. P., Kaderali, L., Hellman, A., Winnefeld, M., & Lyko, F. (2013) · Epigenetics & Chromatin · doi:10.1186/1756-8935-6-36 · Cited by 95
Epigenetic Enzyme Mutations: Role in Tumorigenesis and Molecular Inhibitors
Han, M., Jia, L., Lv, W., Wang, L., & Cui, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00194 · Cited by 99
Epigenetic modifications working in the decidualization and endometrial receptivity
Liu, H., Huang, X., Mor, G., & Liao, A. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03395-9 · Cited by 92
Stirzaker, C., Song, J. Z., Ng, W., Du, Q., Armstrong, N. J., Locke, W. J., Statham, A. L., French, H. J., Pidsley, R., Valdés‐Mora, F., et al. (2016) · Oncogene · doi:10.1038/onc.2016.297 · Cited by 91
Dehennaut, V., Leprince, D., & Lefebvre, T. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00155 · Cited by 91
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 89
Single-cell sequencing technology applied to epigenetics for the study of tumor heterogeneity
Hu, Y., Shen, F., Yang, X., Han, T., Long, Z., Wen, J., Huang, J., Shen, J., & Guo, Q. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01574-x · Cited by 101
ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis
Okochi‐Takada, E., Hattori, N., Tsukamoto, T., Miyamoto, K., Ando, T., Ito, S., Yamamura, Y., Wakabayashi, M., Nobeyama, Y., & Ushijima, T. (2013) · Oncogene · doi:10.1038/onc.2013.174 · Cited by 91
The Impact of DNA Methylation in Hematopoietic Malignancies
Guillamot, M., Cimmino, L., & Aifantis, I. (2016) · Trends in cancer · doi:10.1016/j.trecan.2015.12.006 · Cited by 96
Cai, Y., Tsai, H.-C., Yen, R.-W. C., Zhang, Y. W., Kong, X., Wang, W., Xia, L., & Baylin, S. B. (2017) · Genome Research · doi:10.1101/gr.208108.116 · Cited by 89
Self-citationChu, B. F., Karpenko, M., Liu, Z., Aimiuwu, J., Villalona-Calero, M. A., Chan, K. K. L., Grever, M. R., & Otterson, G. A. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1986-8 · Cited by 90
de Vries, N. A., Hulsman, D., Akhtar, W., de Jong, J., Miles, D. C., Blom, M., van Tellingen, O., Jonkers, J., & van Lohuizen, M. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.028 · Cited by 93
Algorithmic methods to infer the evolutionary trajectories in cancer progression
Caravagna, G., Graudenzi, A., Ramazzotti, D., Pamplona, R. S., Sano, L. D., Mauri, G., Moreno, V. R., Antoniotti, M., & Mishra, B. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520213113 · Cited by 89
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma
Chatterjee, A., Rodger, E. J., Ahn, A., Stockwell, P. A., Parry, M. F., Motwani, J., Gallagher, S. J., Shklovskaya, E., Tiffen, J. C., Eccles, M. R., et al. (2018) · iScience · doi:10.1016/j.isci.2018.05.021 · Cited by 92
Costea, T., Vlad, O., Miclea, L. C., Ganea, C., Szöllõsi, J., & Mocanu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020401 · Cited by 93
The epigenetic regulatory mechanism of PIWI/piRNAs in human cancers
Zhang, Q., Zhu, Y., Cao, X., Tan, W., Yu, J., Lu, Y., Kang, R., Wang, X., & Li, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01749-3 · Cited by 90
The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma
Oca, R. M. D., Gurard‐Levin, Z. A., Berger, F., Rehman, H., Martel, E., Corpet, A., de Koning, L., Vassias, I., Wilson, L. O. W., Meseure, D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.11.002 · Cited by 90
Nagaraju, G. P., Zhu, S., Wen, J., Farris, A. B., Adsay, V. N., Diaz, R., Snyder, J. P., Shoji, M., & El‐Rayes, B. F. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.002 · Cited by 91
Particle Carriers for Combating Multidrug-Resistant Cancer
Yan, Y., Björnmalm, M., & Caruso, F. (2013) · ACS Nano · doi:10.1021/nn405632s · Cited by 89
Developing Targeted Therapies That Exploit Aberrant Histone Ubiquitination in Cancer
Jeusset, L. M., & McManus, K. J. (2019) · Cells · doi:10.3390/cells8020165 · Cited by 95
Adam, S., Anteneh, H., Hornisch, M., Wagner, V., Lu, J., Radde, N. E., Bashtrykov, P., Song, J., & Jeltsch, A. (2020) · Nature Communications · doi:10.1038/s41467-020-17531-8 · Cited by 88
Targeted p16Ink4a epimutation causes tumorigenesis and reduces survival in mice
Yu, D.-H., Waterland, R. A., Zhang, P., Schady, D. A., Chen, M.-H., Guan, Y., Gadkari, M., & Shen, L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76507 · Cited by 88
Borgés, S., Döppler, H. R., Perez, E. A., Andorfer, C. A., Sun, Z., Anastasiadis, P. Z., Thompson, E. A., Geiger, X. J., & Störz, P. (2013) · Breast Cancer Research · doi:10.1186/bcr3460 · Cited by 94
Intra‐tumour heterogeneity – going beyond genetics
Caiado, F., Silva‐Santos, B., & Norell, H. (2016) · FEBS Journal · doi:10.1111/febs.13705 · Cited by 87
DNA Methylation in Cancer: A Gene Silencing Mechanism and the Clinical Potential of Its Biomarkers
Fukushige, S., & Horii, A. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.173 · Cited by 88
Rodríguez‐Paredes, M., Bormann, F., Raddatz, G., Gutekunst, J., Lucena-Porcel, C., Köhler, F., Wurzer, E., Schmidt, K., Gallinat, S., Wenck, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03025-1 · Cited by 90
Osawa, T., Tsuchida, R., Muramatsu, M., Shimamura, T., Wang, F., Suehiro, J., Kanki, Y., Wada, Y., Yuasa, Y., Aburatani, H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3231 · Cited by 88
Tian, X., Zhang, S., Liu, H., Zhang, Y., Blair, C., Mercola, D., Sassone‐Corsi, P., & Zi, X. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313050007 · Cited by 90
Readers of DNA methylation, the MBD family as potential therapeutic targets
Ginder, G. D., & Williams, D. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.002 · Cited by 92
A Structural Perspective on Readout of Epigenetic Histone and DNA Methylation MarksPreprint
Patel, D. J. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018754 · Cited by 91
RETRACTED ARTICLE: Molecular mechanisms in progression of HPV-associated cervical carcinogenesis
Gupta, S. M., & Mania‐Pramanik, J. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0520-2 · Cited by 91
RetractedVinson, C., & Chatterjee, R. (2012) · Epigenomics · doi:10.2217/epi.12.55 · Cited by 89
Diao, Y., Guo, X. H., Jiang, L., Wang, G., Zhang, C., Wan, J., Jin, Y. J., & Wu, Z. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.494716 · Cited by 86
Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
Bewersdorf, J. P., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718816698 · Cited by 88
Pastore, A., Gaiti, F., Lu, S. X., Brand, R. M., Kulm, S., Chaligné, R., Gu, H., Huang, K. Y., Stamenova, E. K., Béguelin, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09645-5 · Cited by 88
TET repression and increased DNMT activity synergistically induce aberrant DNA methylation
Takeshima, H., Niwa, T., Yamashita, S., Takamura‐Enya, T., Iida, N., Wakabayashi, M., Nanjo, S., Abe, M., Sugiyama, T., Kim, Y.-J., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci124070 · Cited by 85
Epigenetic Deregulation of Apoptosis in Cancers
Ozyerli‐Goknar, E., & Onder, T. B. (2021) · Cancers · doi:10.3390/cancers13133210 · Cited by 94
Functional DNA demethylation is accompanied by chromatin accessibility
Pandiyan, K., You, J. S., Yang, X., Dai, C., Zhou, X. J., Baylin, S. B., Jones, P. A., & Liang, G. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt077 · Cited by 89
Self-citationThe extracellular matrix niche microenvironment of neural and cancer stem cells in the brain
Reinhard, J., Brösicke, N., Theocharidis, U., & Faissner, A. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.002 · Cited by 87
Retinoids induce stem cell differentiation via epigenetic changes
Gudas, L. J. (2013) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2013.08.002 · Cited by 85
Sun, Z., Dai, N., Borgaro, J. G., Quimby, A., Sun, D., Junior, I. R. C., Zheng, Y., Zhu, Z., & Guan, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.035 · Cited by 86
Development and classes of epigenetic drugs for cancer
Dhanak, D., & Jackson, P. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.006 · Cited by 83
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 88
Self-citationMOF Acetylates the Histone Demethylase LSD1 to Suppress Epithelial-to-Mesenchymal Transition
Luo, H., Shenoy, A. K., Li, X., Jin, Y., Jin, L., Cai, Q., Tang, M., Liu, Y., Chen, H., Reisman, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.050 · Cited by 85
p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
Sonnemann, J., Marx, C., Becker, S., Wittig, S., Palani, C. D., Krämer, O. H., & Beck, J. F. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.742 · Cited by 87
Wang, P., Wang, Y., Chen, X., Shen, Z., Cao, H., Zhang, Y., Yu, J., Zhu, J., Lu, Y., & Fang, J. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02292.x · Cited by 85
Søes, S., Daugaard, I., Sørensen, B. S., Carus, A., Mattheisen, M., Alsner, J., Overgaard, J., Hager, H., Hansen, L. L., & Kristensen, L. S. (2014) · Oncoscience · doi:10.18632/oncoscience.42 · Cited by 85
MLL-AF9– and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C
Zhu, N., Chen, M., Eng, R., DeJong, J., Sinha, A. U., Rahnamay, N. F., Koche, R. P., Al‐Shahrour, F., Minehart, J. C., Chen, C.-W. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82978 · Cited by 87
Epigenetic memory in response to environmental stressors
Vineis, P., Chatziioannou, A. A., Cunliffe, V. T., Flanagan, J. M., Hanson, M. A., Kirsch‐Volders, M., & Kyrtopoulos, S. Α. (2017) · The FASEB Journal · doi:10.1096/fj.201601059rr · Cited by 87
Integrating the Epigenome to Identify Drivers of Hepatocellular Carcinoma
Hlady, R. A., Sathyanarayan, A., Thompson, J. J., Zhou, D., Wu, Q., Pham, K., Lee, J., Liu, C., & Robertson, K. D. (2019) · Hepatology · doi:10.1002/hep.30211 · Cited by 102
Kim, W., Holcomb, T., Januario, T., Du, P., Evangelista, M., Kartha, N., Iniguez, L. A., Soriano, R. H., Huw, L. Y., Stern, H. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2635-t · Cited by 86
Chung, F. F., & Herceg, Z. (2020) · Environmental Health Perspectives · doi:10.1289/ehp6104 · Cited by 89
Epigenetics in the hematologic malignancies
Fong, C. Y., Morison, J., & Dawson, M. A. (2014) · Haematologica · doi:10.3324/haematol.2013.092007 · Cited by 87
Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
Parker, H., Rose-Zerilli, M. J. J., Larráyoz, M., Clifford, R. M., Edelmann, J., Blakemore, S. J., Gibson, J., Wang, J., Ljungström, V., Wojdacz, T. K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.134 · Cited by 84
LncRNAs as Chromatin Regulators in Cancer: From Molecular Function to Clinical Potential
Begolli, R., Sideris, N., & Giakountis, A. (2019) · Cancers · doi:10.3390/cancers11101524 · Cited by 90
Teh, M., Gemenetzidis, E., Patel, D., Tariq, R., Nadir, A., Bahta, A. W., Waseem, A., & Hutchison, I. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034329 · Cited by 83
Alakhova, D. Y., Zhao, Y., Li, S., & Kabanov, A. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072238 · Cited by 85
Epigenetics in diabetic nephropathy, immunity and metabolism
Keating, S. T., van Diepen, J. A., Riksen, N. P., & El-Osta, A. (2018) · Diabetologia · doi:10.1007/s00125-017-4490-1 · Cited by 82
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Krebs, A. R., Dessus-Babus, S., Burger, L., & Schübeler, D. (2014) · eLife · doi:10.7554/elife.04094 · Cited by 81
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma
Parrish, J. K., Sechler, M., Winn, R. A., & Jedlicka, P. (2013) · Oncogene · doi:10.1038/onc.2013.541 · Cited by 84
Genetic Susceptibility to Head and Neck Squamous Cell Carcinoma
Lacko, M., Braakhuis, B. J. M., Sturgis, E. M., Boedeker, C. C., Suarez, C. M., Rinaldo, A., Ferlito, A., & Takes, R. P. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.09.034 · Cited by 88
DNA Methylation, Nuclear Organization, and Cancer
Madakashira, B. P., & Sadler, K. C. (2017) · Frontiers in Genetics · doi:10.3389/fgene.2017.00076 · Cited by 80
Markopoulos, G. S., Roupakia, E., Marcu, K. B., & Kolettas, E. (2019) · Cells · doi:10.3390/cells8101143 · Cited by 84
Epigenetic Regulation of microRNAs in Cancer: Shortening the Distance from Bench to Bedside
Pajares, M. J., Alemany-Cosme, E., Goñi, S., Bandrés, E., Palanca-Ballester, C., & Sandoval, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147350 · Cited by 82
Ren, J., Li, N., Pei, S., Lian, Y., Li, L., Peng, Y., Liu, Q., Guo, J., Wang, X., Han, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153167 · Cited by 85
Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis
McCleary‐Wheeler, A. L., Lomberk, G. A., Weiß, F. U., Schneider, G., Fabbri, M., Poshusta, T. L., Dusetti, N., Baumgart, S., Iovanna, J., Ellenrieder, V., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.005 · Cited by 86
Noreen, F., Röösli, M., Gaj, P., Pietrzak, J., Weis, S., Urfer, P., Reguła, J., Schär, P., & Truninger, K. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju161 · Cited by 83
Wolff, F., Leisch, M., Greil, R., Risch, A., & Pleyer, L. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-017-0168-z · Cited by 85
Epigenomics of cancer – emerging new concepts
Hassler, M. R., & Egger, G. (2012) · Biochimie · doi:10.1016/j.biochi.2012.05.007 · Cited by 85
Targeting epigenetic regulators for cancer therapy
Wee, S., Dhanak, D., Li, H., Armstrong, S. A., Copeland, R. A., Sims, R. J., Baylin, S. B., Liu, X. S., & Schweizer, L. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12356 · Cited by 81
Self-citationGevensleben, H., Holmes, E. E., Goltz, D., Dietrich, J., Sailer, V., Ellinger, J., Dietrich, D., & Kristiansen, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13161 · Cited by 82
Crosstalk of intracellular post-translational modifications in cancer
Wu, Z., Huang, R., & Yuan, L. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108138 · Cited by 81
The “virgin birth”, polyploidy, and the origin of cancer
Erenpreisa, J. A., Salmiņa, K., Huna, A., Jackson, T., Vázquez‐Martín, A., & Cragg, M. S. (2014) · Oncoscience · doi:10.18632/oncoscience.108 · Cited by 83
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Daskalakis, M., Brocks, D., Sheng, Y.-H., Islam, S., Ressnerova, A., Assenov, Y., Milde, T., Oehme, I., Witt, O., Goyal, A., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442623 · Cited by 90
New insights into prostate cancer stem cells
Chen, X., Rycaj, K., Liu, X., & Tang, D. G. (2013) · Cell Cycle · doi:10.4161/cc.23721 · Cited by 80
DNA methylation, microRNAs, and their crosstalk as potential biomarkers in hepatocellular carcinoma
Anwar, S. L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i24.7894 · Cited by 79
Epigenetics of breast cancer: Modifying role of environmental and bioactive food compounds
Romagnolo, D. F., Daniels, K. D., Grunwald, J. T., Ramos, S. A., Propper, C. R., & Selmin, O. I. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201501063 · Cited by 82
Assi, R. E., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000401 · Cited by 80
Methylation Dynamics of RASSF1A and Its Impact on Cancer
Malpeli, G., Innamorati, G., Decimo, I., Bencivenga, M., Kamdje, A. H. N., Perris, R., & Bassi, C. (2019) · Cancers · doi:10.3390/cancers11070959 · Cited by 79
An update on colorectal cancer microenvironment, epigenetic and immunotherapy
Jin, K., Ren, C., Liu, Y., Lan, H., & Wang, Z. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107041 · Cited by 79
Xi, Y., Lin, Y., Guo, W., Wang, X., Zhao, H., Miao, C., Liu, W., Liu, Y., Liu, T., Luo, Y., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00873-8 · Cited by 79
Epigenetic reprogramming in cancer: From diagnosis to treatment
Costa, P. M. S., Sales, S. L. A., Pinheiro, D. P., Pontes, L. Q., Maranhão, S. S., Pessoa, C., Furtado, G. P., & Furtado, C. L. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1116805 · Cited by 89
Common features of chromatin in aging and cancer: cause or coincidence?
Zane, L. K., Sharma, V., & Misteli, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.001 · Cited by 79
Cancer: pathological nuclear reprogramming?
Goding, C. R., Pei, D., & Lü, X. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3781 · Cited by 82
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 83
Wang, P., Song, Q., Ren, J., Zhang, W., Wang, Y., Zhou, L., Wang, D., Chen, K., Jiang, L., Zhang, B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abp8704 · Cited by 79
Koues, O. I., Kowalewski, R., Chang, L., Pyfrom, S., Schmidt, J. A., Luo, H., Sandoval, L., Hughes, T. B., Bednarski, J. J., Cashen, A. F., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.12.021 · Cited by 81
DNA Methylation in the Malignant Transformation of Meningiomas
Gao, F., Shi, L., Russin, J. J., Zeng, L., Chang, X., He, S., Chen, T. C., Giannotta, S. L., Weisenberger, D. J., Zada, G., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054114 · Cited by 77
Links between DNA methylation and nucleosome occupancy in the human genome
Collings, C. K., & Anderson, J. N. (2017) · Epigenetics & Chromatin · doi:10.1186/s13072-017-0125-5 · Cited by 77
Metadata
- Authors
- Baylin, S. B., & Jones, P. A.
- Affiliations
- Johns Hopkins University (US)
- University of Southern California (US)
- Corresponding author
- Baylin, Stephen B.
- Jones, Peter A.
- Venue
- Nature Reviews Cancer
- Published
- 2011-09-23
- Volume
- 11
- Issue
- 10
- Pages
- 726-734
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3307543
- OpenAlex
- W2041686632
- Cited by
- 2,871
- References
- 166
- Citations by year
- 2026: 105 · 2025: 107 · 2024: 130 · 2023: 148 · 2022: 179 · 2021: 207 · 2020: 175 · 2019: 209 · 2018: 192 · 2017: 233 · 2016: 241 · 2015: 248 · 2014: 288 · 2013: 231 · 2012: 171
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (R01CA043318, R37CA082422)
- National Institute of Environmental Health Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cancer epigenome, DNA methylation, chromatin, epigenetic therapy, tumor markers, cancer diagnosis and prognosis, tumor progression, DNA packaging, epigenetic enzymes, cancer metabolism, epigenetic mutations
- MeSH terms
- Animals, Humans, Neoplasms, Genome, Epigenesis, Genetic, History, 20th Century, History, 21st Century, Translational Research, Biomedical, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
